Pharmacokinetics of Ertugliflozin in Hepatic Impairment

Phase 1, open-label trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration at 96 hours and Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity at 96 hours. Started Sep 2014; status: completed.